1). Microbiome and cancer immunotherapy efficacy and toxicity
2). Mechanisms and biomarkers of microbiome in graft-vs-host disease
3). Biology of Enterococcus in immunotherapy
The Peled laboratory seeks to use human specimens and mouse models to understand how the gut microbiome and host immunity regulate one another and how these relationships might be manipulated to improve immunotherapy for patients with cancer.
Cancer immunotherapy hold tremendous promise, but durable responses in most disease types are achieved in only a minority of patients. For example, allogeneic hematopoietic-cell transplantation (allo-HCT) is a curative treatment for hematological malignancies, but its success is limited by relapse, graft-vs-host disease (GVHD), or infection.
We and others have established that GVHD severity and mortality risk after transplantation are in part dependent on the composition of the intestinal microbiota, yet the mechanisms by which this is mediated remain poorly understood.
The Peled laboratory seeks to use human specimens and mouse models to understand how the gut microbiome and host immunity regulate one another and how these relationships might be manipulated to improve immunotherapy for patients with cancer.
Biography
The Peled lab focuses on cancer immunotherapy.
MD, PhD, Albert Einstein College of Medicine
Publication Highlights:
Elkrief A, Waters NR, Smith N, Dai A, Slingerland J, Aleynick N, Febles B, Gogia P, Socci ND, Lumish M, Giardina PA, Chaft JE, Eng J, Motzer RJ, Mendelsohn RB, Markey KA, Zhuang M, Li Y, Yang Z, Hollmann TJ, Rudin CM, van den Brink MRM, Shia J, DeWolf S, Schoenfeld AJ, Hellmann MD, Babady NE, Faleck DM, Peled JU.Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation. Cancer Immunol Res. 2024 Mar 4;12(3):308-321. doi: 10.1158/2326-6066.CIR-23-0498. PubMed PMID: 38108398; PubMed Central PMCID: PMC10932930.
DeWolf S, Elhanati Y, Nichols K, Waters NR, Nguyen CL, Slingerland JB, Rodriguez N, Lyudovyk O, Giardina PA, Kousa AI, Andrlová H, Ceglia N, Fei T, Kappagantula R, Li Y, Aleynick N, Baez P, Murali R, Hayashi A, Lee N, Gipson B, Rangesa M, Katsamakis Z, Dai A, Blouin AG, Arcila M, Masilionis I, Chaligne R, Ponce DM, Landau HJ, Politikos I, Tamari R, Hanash AM, Jenq RR, Giralt SA, Markey KA, Zhang Y, Perales MA, Socci ND, Greenbaum BD, Iacobuzio-Donahue CA, Hollmann TJ, van den Brink MRM, Peled JU. Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse. Sci Transl Med. 2023 Jul 26;15(706):eabq0476. doi: 10.1126/scitranslmed.abq0476. Epub 2023 Jul 26. PubMed PMID: 37494469; PubMed Central PMCID: PMC10758167.
Ponce DM, Alousi AM, Nakamura R, Slingerland J, Calafiore M, Sandhu KS, Barker JN, Devlin S, Shia J, Giralt S, Perales MA, Moore G, Fatmi S, Soto C, Gomes A, Giardina P, Marcello L, Yan X, Tang T, Dreyer K, Chen J, Daley WL, Peled JU, van den Brink MRM, Hanash AM. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract. Blood. 2023 Mar 23;141(12):1389-1401. doi: 10.1182/blood.2021015111. PubMed PMID: 36399701; PubMed Central PMCID: PMC10163318.
Shouval R, Waters NR, Gomes ALC, Zuanelli Brambilla C, Fei T, Devlin SM, Nguyen CL, Markey KA, Dai A, Slingerland JB, Clurman AG, Fontana E, Amoretti LA, Wright RJ, Hohl TM, Taur Y, Sung AD, Weber D, Hashimoto D, Teshima T, Chao NJ, Holler E, Scordo M, Giralt SA, Perales MA, Peled JU, van den Brink MRM. Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation. Clin Cancer Res. 2023 Jan 4;29(1):165-173. doi: 10.1158/1078-0432.CCR-22-1254. PubMed PMID: 36322005; PubMed Central PMCID: PMC9812902.
